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Patients with Epstein Barr virus-positive lymphomas have
decreased CD4(+) T-cell responses to the viral nuclear antigen 1
Abstract
Epstein Barr virus (EBV) causes lymphomas in immune competent and, at increased frequencies, in
immune compromised patients. In the presence of an intact immune system, EBV-associated
lymphomas express in most cases only 3 or fewer EBV antigens at the protein level, always including
the nuclear antigen 1 of EBV (EBNA1). EBNA1 is a prominent target for EBV-specific CD4(+) T cell
and humoral immune responses in healthy EBV carriers. Here we demonstrate that patients with
EBV-associated lymphomas, primarily Hodgkin's lymphoma, lack detectable EBNA1-specific CD4(+)
T-cell responses and have slightly altered EBNA1-specific antibody titers at diagnosis. In contrast, the
majority of EBV-negative lymphoma patients had detectable IFN-gamma expression and proliferation
by CD4(+) T cells in response to EBNA1, and carry EBNA1-specific immunoglobulins at levels similar
to healthy virus carriers. Other EBV antigens, which were not present in the tumors, were recognized in
less EBV positive, than negative lymphoma patients, but detectable responses reached similar CD8(+) T
cell frequencies in both cohorts. Patients with EBV-positive and -negative lymphomas did not differ in
T-cell responses in influenza-specific CD4(+) T cell proliferation and in antibody titers against tetanus
toxoid. These data suggest a selective loss of EBNA1-specific immune control in EBV-associated
lymphoma patients, which should be targeted for immunotherapy of these malignancies.
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Epstein Barr virus (EBV) causes lymphomas in immune compe-
tent and, at increased frequencies, in immune compromised
patients. In the presence of an intact immune system, EBV-associ-
ated lymphomas express in most cases only 3 or fewer EBV anti-
gens at the protein level, always including the nuclear antigen 1 of
EBV (EBNA1). EBNA1 is a prominent target for EBV-speciﬁc
CD41 T cell and humoral immune responses in healthy EBV car-
riers. Here we demonstrate that patients with EBV-associated
lymphomas, primarily Hodgkin’s lymphoma, lack detectable
EBNA1-speciﬁc CD41 T-cell responses and have slightly altered
EBNA1-speciﬁc antibody titers at diagnosis. In contrast, the ma-
jority of EBV-negative lymphoma patients had detectable IFNc
expression and proliferation by CD41 T cells in response to
EBNA1, and carry EBNA1-speciﬁc immunoglobulins at levels sim-
ilar to healthy virus carriers. Other EBV antigens, which were not
present in the tumors, were recognized in less EBV positive, than
negative lymphoma patients, but detectable responses reached
similar CD81 T cell frequencies in both cohorts. Patients with
EBV-positive and -negative lymphomas did not differ in T-cell
responses in inﬂuenza-speciﬁc CD41 T cell proliferation and in
antibody titers against tetanus toxoid. These data suggest a selec-
tive loss of EBNA1-speciﬁc immune control in EBV-associated
lymphoma patients, which should be targeted for immunotherapy
of these malignancies.
' 2008 Wiley-Liss, Inc.
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Epstein Barr virus (EBV) is a human g-herpesvirus that persis-
tently infects more than 90% of the adult human population.1 It
causes tumors of epithelial and B cells origin, and readily trans-
forms human B cells in vitro.2 However, the majority of EBV car-
riers likely controls their infection with this tumor virus by T cell-
mediated immune responses. This is indicated by the increased
incidence of EBV-associated malignancies in immune suppressed
patients. The efﬁcacy of EBV-speciﬁc T-cell immunity is also
documented by adoptive T cell therapy against virus-induced lym-
phomas utilizing in vitro expanded EBV-speciﬁc T cell lines.3
In contrast to EBV-associated lymphomas in immune sup-
pressed individuals, Hodgkin’s lymphoma (HL) is the most fre-
quent EBV-associated lymphoma of immune competent patients
in the western world, and about 40% of these cases are associated
with EBV.4 Like all EBV-associated malignancies that develop in
the presence of a functional immune system, HL expresses only a
subset of EBV antigens, of which only the nuclear antigen 1 of
EBV (EBNA1) is frequently recognized by T cells in healthy EBV
carriers.5 We hypothesized that an absence of EBNA1-speciﬁc im-
munity could predispose individuals to develop EBV-positive
lymphomas. Here, we show that patients with EBV-positive, but
not EBV-negative, lymphomas consistently lack detectable CD41
T cell immune responses to EBNA1.
Material and methods
Patient samples
Lymphoma patients were identiﬁed by their primary oncologists
at the Memorial Sloan-Kettering Cancer Center and referred to
our study at the time of diagnosis. After patients provided
informed consent to participate (conducted with Memorial Sloan-
Kettering Cancer Center and The Rockefeller University IRB
approved policies and consent forms), patients were asked to pro-
vide blood samples to evaluate their immune responses to EBV
antigens and other control antigens. Patient inclusion criteria were
deﬁned as any stable male or female pediatric or adult patient with
a new diagnosis of lymphoma. Only patients with a prior history
of immune suppressive therapies, underlying immune deﬁciencies
(heritable or infectious etiologies), and patients too ill to partici-
pate were excluded. Eighteen patient samples were obtained
through the Children’s Oncology Group (COG) Hodgkin Study
Section. The COG samples were obtained at diagnosis and
included plasma and frozen peripheral blood mononuclear cells
(PBMCs) (when available).
Culture medium
Culture medium RPMI 1640 (GIBCO, Grand Island, NY) was
supplemented with 5% pooled human serum (PHS, Mediatech,
Herndon, VA) and 20 lg/ml of gentamicin (Bio Whittaker,
Walkersville, MD).
Peptide preparation
Peptides were synthesized in collaboration with the Proteomics
Resource Center, Rockefeller University as previously described.6
Collection and preparation of peripheral blood
The Rockefeller University Internal Review Board approved
this study. After patients were identiﬁed by their primary oncolo-
gists, the research study was described and discussed. After
patients provided informed consent, whole blood was collected
via venipuncture under sterile conditions while following univer-
sal precautions. Blood volumes were collected as the lesser of 2,
50 ml or 2 ml/kg. Blood was collected into heparinized vacu-
tainers (BD Vacutainer, Franklin Lakes, NJ) or heparinized
syringes. An aliquot was immediately used for the whole blood in-
tracellular cytokine assay (this assay was not possible to conduct
on the patient samples from COG). The remaining volume, when
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available (often not available with pediatric patients), was used for
PBMC isolation. PBMCs were separated by density gradient cen-
trifugation on Ficoll-Hypaque (Amersham Pharmacia Biotech,
Piscatway, NJ). PBMCs were depleted of platelets by several
washing steps in PBS, and then resuspended in RPMI. PBMCs
from healthy volunteers were prepared in the same manner.
EBER in situ hybridization
In situ hybridization for EBV was performed on formalin-ﬁxed
parafﬁn-embedded tissue sections employing the Bond Max
Autostainer (Vision Biosystems, Mount Waverley, Australia). Fol-
lowing baking and deparafﬁnization, the slides were incubated
with Bond Enzyme (Vision Biosystems) for 15 min after which
the ﬂuorescein-labeled EBV-encoded RNA (EBER) probe (Vision
Biosystems) was applied. Following incubation with the EBER
probe, the tissue sections were incubated with a mouse anti-ﬂuo-
rescein antibody for 25 min, postprimary for 15 min and polymer
for 25 min (Bond Polymer Reﬁne Detection System; Vision Bio-
systems) followed by colorimetric development with diaminoben-
zidine (DAB; Vision Biosystems).
EBNA1, VCA and tetanus toxoid ELISA assays
EBNA1 and viral capsid antigen (VCA)-speciﬁc antibodies
were quantiﬁed from human plasma by EBNA1 and VCA ELISA
assays according to the manufacturer’s instructions (Sigma/Dia-
medix; Miami, FL). Plasma samples from volunteers were diluted
at 1:20 and 1:10 and run in triplicates. EBNA1 and IgG subclass
titers were assessed by evaluating plasma samples from patients
and volunteers at serial dilutions from 1:25 to 1:3,200. After plot-
ting of the absorption values, the point of inﬂection was calculated
to determine the immunoglobulin titer.
Whole blood intracellular cytokine assay
Aliquots of 500 ll of fresh whole blood were placed into 15-ml
snap-top round-bottom polypropylene tubes (Falcon, BD Labware,
Bedford, MA) for a 6 hr incubation at 37C in 5% CO2. Each reac-
tion was carried out in the presence of 1 lg/ml of costimulatory
monoclonal antibodies to CD28 and CD49d (BD Biosciences,
Immunocytometry Systems, San Jose, CA). Each tube also
included 10 lg/ml of Brefeldin A (Sigma, St. Louis, MO). CD41
T-cell positive controls included 750 ng (1.5 lg/ml) of Staphylo-
coccal enterotoxin B (SEB) or inﬂuenza A strain Aichi/68
(Charles River Laboratories, North Franklin, CT) at a concentra-
tion of 106 HAU/ml. In addition, nonameric CD81 T-cell epitopes
of HCMV and EBV (noted as CMV and EBV in ﬁgures) of the
CEF peptide mixture7 were used as peptide controls at a concen-
tration of 1 lM. The EBNA1 peptide mixture consisted of 51
overlapping peptides and was added to a ﬁnal concentration 3.5
lM per peptide per reaction. The used EBNA1 peptide library of
15mers overlapping by 10 amino acids, encoding for the immuno-
genic C-terminal domain (aa400–641) of the protein, was previ-
ously described.6 After the 6 hr incubation, 2 ll of 0.5 M EDTA
was added to each aliquot, and the samples were gently mixed and
left at room temperature for 5 min. Finally, each sample received
4.5 ml of FACS lysing buffer (BD Imunocytometry Systems), and
each sample was vigorously vortexed for 5 sec and left at room
temperature for 10 min prior to storage at 280C overnight. Sam-
ples were thawed at room temperature, and transferred to FACS
tubes. After centrifugation, cells were resuspended in 500 ll of
permeabilization solution (0.1% BSA, 0.1% saponin, in PBS), and
remained at room temperature for 10 min. Permeabilization solu-
tion was decanted after a second centrifugation, and the cells were
stained with mouse anti-human, directly ﬂuorochrome-labeled
antibodies for 10 min at room temperature. Assays were divided
into duplicates or triplicates, and stained with IL-2-FITC, IFNg-
PE, CD3-PerCp, CD4-APC or CD8-APC (all antibodies from BD
Pharmingen, San Diego, CA). Cells were washed with permeabili-
zation solution and resuspended in 200 ll of FACS buffer solution
(0.1% Sodium Azide in PBS). The samples were analyzed on a
FACScalibur ﬂow cytometer (BD Biosciences, San Jose, CA).
Over one million events or 3 3 105 lymphocytes could be ana-
lyzed from each sample. After gating on lymphocytes based on
size, CD41CD31 T cells were analyzed for expression of IFNg or
IL-2. Expression of greater than 10 IFNg1 T cells above twice the
frequency observed to background deﬁned a positive response.
Approximately 23 105 CD41 T cells were evaluated for IFNg ex-
pression per reaction. Gates to identify IFNg or IL-2 positive cells
were determined by comparison to mouse isotype controls of IgG1-
PE and IgG2b-FITC for IFNg-PE and IL-2-FITC, respectively.
Proliferation assay by CFSE dilution
When enough patient blood was available, PBMCs were iso-
lated from blood samples via density centrifugation. Fresh or fro-
zen PBMCs were washed in PBS and incubated at 37C in 0.3 lM
CFSE (carboxyﬂuorescein succinimidyl ester; Molecular Probes,
Eugene, OR) in PBS at a concentration of 107 cells per ml for 10
min. Cells were washed in PBS and resuspended in 5% PHS with
1 lg/ml of costimulatory monoclonal antibodies to CD28 and
CD49d at a concentration of 1.7 3 106 cells per ml. PBMCs were
distributed at 1 ml or 1.7 3 106 cells per well into 48-well plates.
Known CD81 T-cell epitopes of HCMV and EBV (noted as CMV
and EBV in ﬁgures) of the CEF peptide mixture7 were used as
controls at a concentration of 1 lM. Additional positive controls
included Staphylococcus enterotoxin B (SEB) (Sigma, St. Louis,
MO) at a ﬁnal concentration of 125 ng/ml, and infection of
PBMCs with inﬂuenza A strain Aichi/68 (Charles River Laborato-
ries, North Franklin, CT). Inﬂuenza A infection was achieved by
resuspending PBMCs in RPMI at 107 cells per ml with 50,000
HAU/ml of inﬂuenza A for 1 hr at 37C. After infection, cells
were washed in RPMI and resuspended in 5% PHS for the 6-day
proliferation. EBNA1 peptides were brought to a ﬁnal concentra-
tion of 3.5 lM of each peptide per well. The used EBNA1 peptide
library of 15mers overlapping by 10 amino acids, encoding for the
immunogenic C-terminal domain (aa400–641) of the protein, was
previously described.6 At the conclusion of 6-day incubations at
37C and 5% CO2, cells were harvested and washed once in PBS
and stained with directly ﬂuorochrome-labeled antibodies against
CD3-PE, CD8-PerCP, CD4-APC (all BD Pharmingen, San Diego,
CA) for 10 min at room temperature. The cells were washed once
with PBS and resuspended in 200 ll FACS buffer (0.01% Sodium
Azide in PBS) prior to FACS analysis. The samples were analyzed
on the FACScalibur ﬂow cytometer gating on lymphocytes based
on size. CD31CD41 T cells were gated for analysis of prolifera-
tion of CD41 T cells. In addition, proliferating CD41CD62L1
central memory T cells were evaluated in some experiments. Pro-
liferating cells were analyzed with the FlowJo1 (Tree Star, Ash-
land, OR) software. Cytokine concentrations were determined
from proliferation assay supernatants by Luminex technology
according to the manufacturer’s recommendations (Biosource,
Camarillo, CA).
Luminex assay
Cell supernatants from day 6 proliferation assay cultures were
analyzed for 10 cytokines using the Protein Multiplex Immunoas-
say kit (Biosource International) as per the manufacturer’s proto-
col. In brief, Multiplex beads (Biosource) were vortexed and soni-
cated for 30 sec, and 25 ll was added to each well and washed 2
times with wash buffer. The samples were diluted 1:2 with assay
diluent and loaded onto a Multiscreen BV 96-well ﬁlter plate
(Millipore) with 50 ll of incubation buffer already added to each
well. Serial dilutions of cytokine standards were prepared in paral-
lel and added to the plate. Samples were then incubated on a plate
shaker at 600 rpm in the dark at room temperature for 2 hr. The
plate was applied to a Multiscreen Vacuum Manifold (Millipore)
and washed twice with 200 ll of wash buffer. Hundred microliters
of biotinylated anti-human Multi-Cytokine Reporter (Biosource
International) was added to each well. The plate was incubated on
a plate shaker at 600 rpm in the dark at room temperature for 1 hr.
The plate was applied to a Multiscreen Vacuum Manifold (Milli-
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pore) and washed twice with 200 ll of wash buffer. Streptavidin-
phycoerythrin was diluted 1:10 in wash buffer, and 100 ll was
added directly to each well. The plate was incubated on a plate
shaker at 600 rpm in the dark at room temperature for 30 min. The
plate was then applied to the vacuum manifold, washed twice and
each well was resuspended in 100 ll wash buffer and shaken for 1
min. The assay plate was then transferred to the Bio-Plex Luminex
100 XYP instrument (Millipore) for analysis. Cytokine concentra-
tions were calculated using Bio-Plex Manager 3.0 software with a
5-parameter curve-ﬁtting algorithm applied for standard curve
calculations.
Statistical analysis
Statistical analyses were performed with the paired 2-tailed Stu-
dent’s t-test. The p value of signiﬁcant differences is reported.
Plotted data represent mean plus standard deviation (SD), unless
otherwise stated.
Results
Lack of detectable EBNA1-speciﬁc IFN-c responses by CD41 T
cells in EBV-positive lymphoma patients
In our study, immune responses of 44 lymphoma patients with
no apparent immune deﬁciencies were evaluated at diagnosis
(Table I). The patient cohort included pediatric and adult patients
consisting of 18 males and 26 females (age range: 7 to 73 years
old; mean of 32.2 years). Routine baseline studies indicated that
all patients were immune competent with normal erythrocyte, leu-
kocyte and lymphocyte counts (data not shown). All patients were
serologically EBV-positive by EBNA1 and/or VCA-speciﬁc
ELISA assays, and 19 of these patients had EBV-positive lympho-
mas, as determined by in situ hybridization for nontranslated
EBERs in lymphoma biopsies (data not shown). The remaining 25
patients had EBV-negative lymphomas. Of the EBV-positive lym-
phomas 17, and of the EBV-negative 13 were HL, in both groups
mainly of nodular sclerosing histology.
More than 75% of healthy EBV carriers possess EBNA1-spe-
ciﬁc CD41 T-cell responses,6,9–12 and EBNA1 protein expression
is maintained in all EBV-associated malignancies.13 In contrast,
T-cell responses against the other EBV antigens expressed in HL,
namely the latent membrane proteins LMP1 and LMP2, are de-
tectable in less than 20 and 50% of healthy EBV carriers, respec-
tively.10,14 Therefore, we analyzed if the frequent EBNA1-speciﬁc
CD41 T-cell responses would differ between patients with EBV-
positive and EBV-negative lymphomas. EBNA1-speciﬁc CD41 T
cells from peripheral blood can be identiﬁed by the production of
IFNg and proliferation (CFSE dilution) in response to an overlap-
ping peptide mixture covering the C-terminal domain of the pro-
tein.6 Both for intracellular IFNg staining and proliferation, a posi-
tive responding patient was deﬁned as having frequencies of
responding CD41 T cells of at least 2-fold over background and
consisting of at least 10 responding cells. Only patient samples
that responded to the positive control Staphylococcus enterotoxin
B (SEB), as a measure of T cell reactivity preservation during
sample collection and transport, were included in the analysis,
which led to the exclusion of all COG samples from intracellular
IFNg staining and 9 of 18 from proliferation assays (Table I).
Most patients with EBV-negative lymphomas (10 of 17 or 59%
of tested patients) were identiﬁed as carriers of EBNA1-speciﬁc
CD41 T cells by intracellular IFNg staining (Fig. 1). These
patients had an average of 0.027% (with a range of 0.01 to
0.046%) of EBNA1-speciﬁc among all circulating CD41 T cells.
FIGURE 1 – EBNA1-speciﬁc CD41 T cell derived production of IFNg among patients and healthy volunteers. EBNA1-speciﬁc CD41 T cells
were analyzed by intracellular IFNg staining. CD41 T cell responses in response to medium (no stimulus), SEB, inﬂuenza A viral particle infec-
tion and EBNA1 peptides (EBNA1) are shown. (a) Whole blood assay after gating on lymphocytes, based on size, and on CD41 T cells. The fre-
quency of IFNg1CD41 T cells is indicated. CD41 cells (x-axis) and intracellular cytokine staining for INFg (y-axis) are depicted. The top row
represents detected IFNg responses from 1 of 20 EBV-positive carriers. The second row represents an EBV-seronegative individual. The third
row represents 1 of 17 EBV-seropositive patients with EBER-negative lymphomas and the bottom row is representative of 1 of 9 patients with
an EBER-positive lymphoma. Gates for IFNg positive cells are based on isotype controls. (b) Graph depicting the average frequency of CD41 T
cell production of IFNg in response to the indicated antigens HCMV derived CD81 T cell epitopes (CMV) was used as an additional negative
control.
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Although this response was more common among healthy volun-
teers (18 of 20 or 90%),6 the patient cohort was statistically indis-
tinguishable (average of 0.027% with a range of 0.008 to 0.053%
among all circulating CD41 T cells; student paired t-test p 5
0.35) from this previously described cohort of healthy EBV-car-
riers in the frequency of EBNA1-speciﬁc CD41 T cells. In con-
trast, none of the 9 patients with EBV-positive lymphomas, whose
immune responses could be tested in fresh blood samples, had de-
tectable EBNA1-speciﬁc IFNg producing CD41 T cells. Com-
pared to healthy EBV carriers and patients with EBV-negative
lymphomas, the lack of a detectable EBNA1-speciﬁc CD41 T-cell
response from the tested patients with EBV-positive lymphomas
was statistically signiﬁcant (both p < 0.001) (Fig. 1). Importantly,
when only comparing HL, EBNA1-speciﬁc IFNg producing
CD41 T cells were detected in none of 7 EBV-positive, but 4 of 5
EBV-negative patients (Table I, and Supplemental Figs. 1 and 3).
To show that this cohort of patients had intact cell-mediated
immune responses to other EBV antigens, we analyzed previously
described CD81 T-cell responses against dominant MHC class I
ligands of EBV antigens, which are not present in Hodgkin Reed
Sternberg cells of HL.7 Positive responses of similar magnitude to
these ligands were observed in 3 of 9 (33%) patients with EBV-
positive lymphomas (range of 0.041 to 1.39% among all circulat-
ing CD81 T cells), 11 of 17 (65%) patients with EBV-negative
lymphomas (range of 0.046 to 1.66% among all circulating CD81
T cells) and 14 of 20 (70%) individuals of a previously described
cohort of EBV carriers (range of 0.028 to 1.21% among all circu-
lating CD81 T cells).6 Therefore, CD81 T-cell responses against
these other EBV antigens were detected at similar frequencies, but
less frequently in EBV-positive than negative lymphoma patients.
These data indicate that unlike patients with EBV-negative lym-
phomas and healthy volunteers, the patients with EBV-positive
lymphomas had no detectable EBNA1-speciﬁc effector memory
CD41 T cells, which rapidly produce IFNg in response to the
immunodominant C-terminal domain of EBNA1.
Loss of CD41 T cell proliferation to EBNA1 in
EBV-positive lymphoma patients
To identify the presence of smaller populations of central mem-
ory and non-Th1 polarized EBNA1-speciﬁc CD41 T cells that
may have gone undetected in our intracellular cytokine staining
assay, proliferation assays were conducted, whenever patient
blood samples were of sufﬁcient volume for additional tests. Con-
ﬁrming our ﬁndings with the intracellular IFNg staining assay,
none of the 8 tested patients with EBV-positive lymphomas had
any detectable EBNA1-speciﬁc proliferation. However, 13 out of
16 (81%) EBV-negative lymphoma patients exhibited an average
FIGURE 2 – EBNA1-speciﬁc CD41 T cell proliferation among patients and healthy volunteers. EBNA1-speciﬁc CD41 T cells were analyzed
by CFSE proliferation assays. CD41 T-cell responses in response to medium (no stimulus), SEB, inﬂuenza A viral particle infection and
EBNA1 peptides (EBNA1) are shown. CFSE dilution, or proliferation, was determined after gating on lymphocytes, based on size. The fre-
quency of CFSE dilute (proliferating) CD41 T cells is indicated. Intensity of CFSE (x-axis) and CD41 cells (y-axis) are depicted. The top row
represents proliferation responses from 1 of 20 EBV-positive carriers, samples from an EBV-seronegative individual are shown in the second
row. The third row represents 1 of 16 EBV-seropositive patients with EBER-negative lymphomas and the bottom row is representative of 1 of 8
patients with an EBER-positive lymphoma. Gates for CFSE dilute or proliferating cells are shown.
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proliferation of EBNA1-speciﬁc CD41 T cells 6-fold greater than
background proliferation (range 2.25- to 30-fold). While the fre-
quencies of proliferating EBNA1-speciﬁc CD41 T cells varied
between patients with EBV-negative lymphomas, the difference in
proliferation between EBV-positive and -negative lymphoma
patients was statistically signiﬁcant (p < 0.001). Again, patients
with EBV-negative lymphomas were virtually indistinguishable
from healthy individuals (Fig. 2). When focusing on HL, none of
7 EBV-positive, but 5 of 7 EBV-negative patients demonstrated
EBNA1-speciﬁc CD41 T-cell proliferation (Table I, and Supple-
mental Figs. 2 and 4). In 3 EBV-positive and 6 EBV-negative
lymphoma patients, we performed Luminex analysis for IL-1b,
IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFNg, GM-CSF and TNF-a
from the supernatants of 6 day proliferation assays. While more
GM-CSF and IL-6 was produced in response to EBNA1 in cul-
tures from EBV-negative than from EBV-positive patients, this
difference did not reach statistical signiﬁcance (Supplemental Fig.
5). In addition, Th2 cytokines such as IL-4 and IL-5 were not pro-
duced at detectable amounts (data not shown). Similarly, no sig-
nals for IL-1b, IL-2, IL-8, IL-10, IFNg and TNF-a were detected
(data now shown). Combining intracellular cytokine and prolifera-
tion assays, none out of 12 EBV-positive, but 15 out of 23 (65%)
EBV-negative lymphoma patients, who could be tested for cellular
immune responses in at least one of the assays, showed EBNA1-
speciﬁc CD41 T-cell responses. In the other 7 EBV-positive and 2
EBV-negative lymphoma patients of the COG samples group T-
cell responses against the positive control SEB could not be
detected, probably due to poor T-cell recovery from the cryopre-
served PBMCs, and, therefore, the EBNA1-speciﬁc T-cell
responses could not be interpreted. Importantly, none of 10 EBV-
positive, but 9 of 11 EBV-negative HL patients had detectable
EBNA1-speciﬁc IFNg production or proliferation by CD41 T
cells (Supplemental Figs. 1–4). In addition, 3 of 3 EBV-positive
(100%) and 9 of 12 EBV-negative (75%) lymphoma patients dem-
onstrated inﬂuenza-speciﬁc CD41 T-cell responses either by intra-
cellular cytokine staining or proliferation. The lack of both CD41
T cell IFNg production and CD41 T cell proliferation in response
to EBNA1 in the face of EBNA1-positive serology and EBV-posi-
tive lymphomas prompted a more thorough evaluation of these
patients’ EBNA1-speciﬁc immunoglobulin titers.
EBNA1-speciﬁc IgG4 in some EBV-positive lymphoma patients
Plasma samples from each patient and 20 healthy EBV-carriers
were evaluated for the quantiﬁcation of IgG subclass titers (Fig.
3a). Every healthy EBV-carrier had detectable EBNA1-speciﬁc
IgG1 titers (range 1:62 to 1:840 with a mean of 1:344). Only one
healthy volunteer had a detectable IgG2 titer (1:470). Among the
lymphoma patients, 19 of 25 (76%) of the patients with EBV-neg-
ative lymphomas, and 17 of 19 (89%) of the patients with EBV-
positive lymphomas had detectable EBNA1-speciﬁc IgG titers
with IgG1 as the most commonly detected immunoglobulin iso-
type (with average titers of 1:504 and 1:338, respectively).
Although there was no signiﬁcant difference between IgG1-4 titers
between EBV-negative lymphoma patients and healthy virus car-
riers, the patient cohort of EBV-positive lymphoma patients con-
FIGURE 3 – Immunoglobulin titers to EBNA1 and tetanus toxoid among patients and healthy carriers. Average immunoglobulin G isotype
titers from the healthy and patient cohorts are shown in this ﬁgure. (a) Average immunoglobulin titers to EBNA1 are compared from 20 healthy
EBV carriers, 25 EBV-seropositive patients with EBER-negative lymphomas and 19 patients with EBER-positive lymphomas. Ratios of patients
or volunteers with positive or detectable titers are outlined in table below graph. Although all 3 cohorts had similar IgG1, IgG2 and IgG3 titers,
only patients from the EBV-positive lymphoma cohort had a detectable EBNA1-speciﬁc IgG4 titer. This was statistically signiﬁcant compared
to both healthy and EBV-negative lympohoma cohorts (p < 0.005). (b) Average immunoglobulin titers to tetanus toxoid are compared from 12
healthy EBV-seropositive volunteers, 25 EBV-seropositive patients with EBER-negative lymphomas and 19 patients with EBER-positive lym-
phomas. Ratios of patients or volunteers with positive or detectable titers are outlined in table below graph. All 3 cohorts had similar IgG1,
IgG2, IgG3 and IgG4 titers.
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tained 1 patient, which had only an EBNA1-speciﬁc IgG2 titer,
and 4 patients, which had detectable IgG4 titers (titers ranged
from 1:210 to 1:700, mean of 1:462; p < 0.005), the latter being
associated with Th2 polarized immune responses.15,16 Although
the patient populations differed with lower IgG1 and occasional
IgG4 titers in the anti-EBNA1 antibody responses, there were no
appreciable differences seen when their plasma samples were
assessed for anti-tetanus toxoid titers (Fig. 3b). Therefore, most
lymphoma patients in this study maintained EBNA1-speciﬁc hu-
moral immune responses, primarily mediated through IgG1 anti-
bodies. However, 21% of tested EBV-positive, but none of the
EBV-negative HL patients had developed EBNA1-speciﬁc IgG4
responses in addition.
Discussion
General immune suppression promotes the emergence of lym-
phoproliferative disease, expressing numerous EBV antigens. Our
study suggests that immune competent individuals may only be
susceptible to EBV-positive lymphomas, if they lack immune
responses to the most frequently recognized target of CD41 T-cell
responses among HL-associated antigens, namely toward EBNA1.
Loss of the CD41 T-cell response to the limited group of EBV
antigens present in EBV-associated lymphomas might be espe-
cially dangerous, since helper T cells orchestrate adaptive immune
responses and are required to maintain CD81 T cell functional-
ity,17 in addition to their direct antiviral functions.18 Therefore,
CD81 T-cell responses against for example the latent membrane
protein 2 (LMP2), which is also expressed in HL, might not be
able to keep EBV’s transformation potential in check without
CD41 T cell help. Vulnerability to EBV-associated tumorigenesis
by decreased EBNA1-speciﬁc CD41 T-cell responses might exist
prior to HL development or be induced by immune suppressive
mechanisms of the tumor cells themselves. Alternatively, these T
cells could be depleted from the periphery by homing to the tumor
tissue without being able to clear the lymphoma at these sites.
The presence of EBNA1-speciﬁc antibody responses suggests
that EBNA1-speciﬁc CD41 T cell help was present during the pri-
mary immune response to EBV, but then might have been lost or
diminished below the detection limit of the assays used in this
study, during or prior to tumorigenesis. In addition, a subset of
individuals that acquire EBV by symptomatic EBV infection
called infectious mononucleosis (IM) have been described to lack
EBNA1-speciﬁc antibody responses,19 and IM confers a 4-fold
higher risk to develop HL with a median incubation time of 4
years after IM resolution.20 This might indicate that a subset of IM
patients acquire EBV without developing EBNA1-speciﬁc CD41
T-cell responses, predisposing them to develop HL. While Th2
associated EBNA1-speciﬁc IgG4 responses were observed in
some EBV-positive HL patients, the very same patients did not
demonstrate EBNA1-speciﬁc CD41 T cell proliferation nor was
there a signiﬁcant increase in Th2 associated cytokines in the
supernatants of these proliferation assays as measured by Lumi-
nex. This argues against skewing of the EBNA1-speciﬁc CD41 T-
cell response from protective Th1 polarization to tumor growth
promoting Th2 polarization11,21 as a general pathomechanism in
HL. In some patients (20%), however, who later developed EBV-
positive lymphomas, Th2 polarized T cells speciﬁc for EBNA1
might have been present, and then lost prior or during tumorigene-
sis, as indicated by the persisting IgG4 antibodies and lack of
CD41 T cell proliferation to this antigen. Therefore, our data sug-
gest general loss of EBNA1-speciﬁc CD41 T cell control as a pre-
disposing or promoting factor for the development of EBV-posi-
tive HL in the majority of patients.
An initially diminished immune response to EBNA1, combined
with immune evasion strategies by Hodgkin Reed Sternberg cells,
like IL-1322 and galectin-1 production,23 as well as regulatory T
cell induction,24,25 might have allowed the tumor to escape EBV-
speciﬁc immune control in lymphoma patients. Similar to our ﬁnd-
ings in HL, endemic Burkitt’s lymphoma patients seem to have
decreased EBNA1-speciﬁc CD41 T-cell responses in the presence
of intact humoral immune responses to EBNA1 (Ann Moormann,
personal communication). In addition to EBNA1-speciﬁc CD41 T
cell loss in spontaneous EBV-positive Hodgkin’s and Burkitt’s
lymphomas, 2 independent groups reported that selective EBV-
speciﬁc CD41 T cell depletion by human immunodeﬁciency virus
(HIV), even after recovery of total CD41 T cell numbers under
antiretroviral therapy (ART), predisposed and accompanied EBV
associated non-Hodgkin’s lymphoma (NHL)26 and CNS lym-
phoma.27 Interestingly, primarily loss of EBNA1-speciﬁc CD41 T
cells, even when CD41 T-cell responses against the lytic antigen
BZLF1 recovered under ART, was associated with NHL develop-
ment.26 Consistent with a hole in EBV-speciﬁc immune control,
rather than the general loss of immune responses against this virus
in HIV-infected individuals, EBV viral load, also established at a
new setpoint during HIV infection, was stable and not predictive
for EBV associate lymphoma development.28 Our studies together
with previously published information on HIV-associated EBV-
positive malignancies suggest that selective loss of EBNA1-spe-
ciﬁc CD41 T cell control is associated with EBV-positive lym-
phoma development, but the mechanism behind this loss remains
unclear.
Regardless of the cause of diminished EBNA1-speciﬁc CD41
T-cell responses in EBV-positive lymphoma patients, our study
suggests that immunotherapeutic strategies should be developed to
stimulate this arm of EBV-speciﬁc immune control. In addition, it
should be considered to develop EBNA1-based vaccines, which
could be used to prevent the symptomatic EBV infection IM, as
well as the increased risk to develop HL following IM.20
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